Rep. April McClain Delaney Sells IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock

Representative April McClain Delaney (D-Maryland) recently sold shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX). In a filing disclosed on November 04th, the Representative disclosed that they had sold between $1,001 and $15,000 in IDEXX Laboratories stock on October 16th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Teledyne Technologies (NYSE:TDY) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Labcorp (NYSE:LH) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Tractor Supply (NASDAQ:TSCO) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 10/29/2025.
• Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 10/29/2025.
• Purchased $1,001 – $15,000 in shares of Labcorp (NYSE:LH) on 10/29/2025.
• Sold $1,001 – $15,000 in shares of Middleby (NASDAQ:MIDD) on 10/22/2025.
• Purchased $15,001 – $50,000 in shares of Nasdaq (NASDAQ:NDAQ) on 10/22/2025.

IDEXX Laboratories Stock Down 0.9%

Shares of IDXX opened at $713.74 on Friday. The company has a market cap of $57.10 billion, a P/E ratio of 59.43, a P/E/G ratio of 4.06 and a beta of 1.62. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $735.00. The firm has a 50 day simple moving average of $644.05 and a two-hundred day simple moving average of $576.13.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.26. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm’s revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on IDXX. Leerink Partners set a $785.00 price target on IDEXX Laboratories in a report on Monday. Morgan Stanley boosted their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday. UBS Group lifted their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a report on Tuesday. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a report on Monday. Finally, BTIG Research increased their target price on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $730.50.

Hedge Funds Weigh In On IDEXX Laboratories

Institutional investors and hedge funds have recently modified their holdings of the stock. Mutual of America Capital Management LLC lifted its holdings in shares of IDEXX Laboratories by 79.6% during the first quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock worth $8,160,000 after purchasing an additional 8,609 shares during the period. Arkadios Wealth Advisors acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $405,000. Plato Investment Management Ltd increased its position in shares of IDEXX Laboratories by 37.1% in the first quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock valued at $1,310,000 after buying an additional 835 shares in the last quarter. Genesis Wealth Advisors LLC acquired a new position in IDEXX Laboratories during the second quarter worth $215,000. Finally, ORG Wealth Partners LLC purchased a new position in IDEXX Laboratories in the 2nd quarter valued at about $273,000. 87.84% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Michael G. Erickson sold 406 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total transaction of $263,883.76. Following the transaction, the executive vice president owned 11,287 shares of the company’s stock, valued at approximately $7,336,098.52. This represents a 3.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Nimrata Hunt sold 1,200 shares of the stock in a transaction on Monday, August 11th. The shares were sold at an average price of $656.53, for a total value of $787,836.00. Following the completion of the sale, the executive vice president owned 16,807 shares in the company, valued at approximately $11,034,299.71. The trade was a 6.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,793 shares of company stock worth $2,467,430 over the last three months. Insiders own 0.98% of the company’s stock.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.